Patients with gastrointestinal tumors may have increased risk of developing other cancers
the ONA take:
According to a recent study published in the journal Cancer, researchers at the University of California San Diego School of Medicine have found that patients with gastrointestinal stromal tumors (GIST) have a higher risk of developing additional malignancies before and after their diagnosis of GIST.
Specifically, the study showed that one in 5.8 patients with GIST will develop other sarcomas, carcinoid tumors, non-Hodgkin's lymphoma, melanoma, breast, colorectal, esophageal, hepatobiliary, non-small cell lung, pancreatic, prostate, and renal cell cancers.
Results also showed that when compared to the general U.S. population, patients with GIST had a 44% increased prevalence of cancers occurring before a diagnosis of GIST and a 66% increased risk of developed other cancers following diagnosis.
"Patients diagnosed with gastrointestinal stromal tumors may warrant consideration for additional screenings based on the other cancers that they are most susceptible to contract," said co-author James D. Murphy, MD, assistant professor of radiation oncology and UC San Diego Moores Cancer Center radiation oncologist.
Patients with gastrointestinal stromal tumors have a higher risk of developing additional malignancies before and after diagnosis.
- Response to Anemia Treatment Differs in Lymphoma, Multiple Myeloma
- Fertility Preservation in Male Adolescents and Young Adults With Cancer
- Impact of Prostate Cancer Diagnosis, Treatment Choice on Quality of Life
- Social, Psychiatric Variables Reduce Cognitive Functioning, QoL in HNC
- Axillary Lymph Node Dissection Predictive for Lymphedema in Breast Cancer
- HPV and Cancer (Fact Sheet)
- Pain Control More Easily Achieved With Nurse-Led Education in Bone Metastases
- Acupuncture an Effective Alternative Treatment for Cancer-Related Fatigue
- Using Nutrition-Based Strategies to Manage Adverse Effects of Cancer
- Palliative Care Associated With Decreased Costs For Patients With Advanced Cancer
- Refined Equation May Obviate Oncotype DX in Breast Cancer Treatment Decisions
- Risk Factors for Brain Metastases in HER2+ Breast Cancer Identified in Analysis
- Intermediate Oncotype DX Scores Prognostic of OS in Early-stage Breast Cancer
- Colorectal Cancer and Dietary Fiber: Source Is More Important Than Amount
- Reduced Delayed Intensification Impacts Risk of Pediatric ALL Relapse
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|